Market Overview

Goldman Sachs Places Centene EPS and PT Under Review

Share:
Related CNC
Barclays Raises Price Targets On Healthcare Companies
8 Managed Care Stocks Wells Fargo Is Watching
Health Stocks Lead The Pack In Q1; Are They Fading? (Investor's Business Daily)

Goldman Sachs has published a research report on Centene (NYSE: CNC) commenting on lowered guidance from new market utilization pressures.

In the report, Goldman Sachs writes, "CNC revised its 2012 EPS guidance downwards, reflecting higher than anticipated medical costs in its new Texas and Kentucky markets, as well as for its individual commercial business (Celtic). CNC now sees 2012 EPS of $1.45-$1.65 vs. prior $2.64-$2.84 and anticipates a loss for 2Q2012. We expect CNC will provide further detail at its investor day this Thursday."

Goldman Sachs has EPS and price target for Centene under review, while the stock is trading down $9.27 from Friday's $35.47 closing price.

Latest Ratings for CNC

DateFirmActionFromTo
Mar 2015BarclaysMaintainsOverweight
Feb 2015BarclaysMaintainsOverweight
Feb 2015Deutsche BankMaintainsHold

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color News Guidance Reiteration Analyst Ratings

 

Related Articles (CNC)

Around the Web, We're Loving...